These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3. Madsen S Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650 [No Abstract] [Full Text] [Related]
3. The effect of plasma phosphate on the action of 1alphaOHD3 in haemodialysis patients. Peacock M; Davison AM; Walker GS Adv Exp Med Biol; 1977; 81():559-69. PubMed ID: 899940 [No Abstract] [Full Text] [Related]
4. Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alpha-hydroxyvitamin D3. Peacock M; Aaron JE; Walker GS; Davison AM Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():73s-81s. PubMed ID: 606428 [No Abstract] [Full Text] [Related]
6. Effects of 1alpha-hydroxyvitamin D3 on serum calcium and immunoreactive parathyroid hormone in patients with chronic renal insufficiency. Pietrek J; Kokot F; Kuska J Int Urol Nephrol; 1978; 10(2):153-60. PubMed ID: 700946 [TBL] [Abstract][Full Text] [Related]
7. Effects of 25-hydroxycholecalciferol on calcium metabolism in chronic renal failure. Letteri JM; Kleinman LM; Ellis KN; Caselnova R; Akhtar M; Cohn SH Adv Exp Med Biol; 1977; 81():591-601. PubMed ID: 899943 [No Abstract] [Full Text] [Related]
8. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease. Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; De Luca HF Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662 [No Abstract] [Full Text] [Related]
9. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy. Massry SG; Goldstein DA; Malluche HH Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981 [No Abstract] [Full Text] [Related]
11. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy. Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125 [TBL] [Abstract][Full Text] [Related]
12. Effect of 1alpha-hydroxyvitamin D3 on parathyroid function in patients with chronic renal failure. Nielsen HE; Christensen MS; Melsen F; Rømer FK; Hansen HE Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():67s-72s. PubMed ID: 606427 [TBL] [Abstract][Full Text] [Related]
13. Short-term effects of varying doses of 1 alpha-hydroxyvitamin D3 on blood and urine chemistry and calcium absorption of osteoporotic patients. Lindholm TS; Sevastikoglou JA; Lindgren U Clin Orthop Relat Res; 1978 Sep; (135):226-31. PubMed ID: 709935 [TBL] [Abstract][Full Text] [Related]
14. Correlation of clinical, biochemical and skeletal responses to 1alpha-hydroxyvitamin D3 in renal bone disease. Kanis JA; Earnshaw M; Henderson RG; Heynen G; Ledingham JG; Naik RB; Oliver DO; Russell RG; Smith R; Wilkinson RH; Woods CG Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():45s-50s. PubMed ID: 606424 [TBL] [Abstract][Full Text] [Related]
15. The action of 1alphahydroxy vitamin D3 and phosphate supplements in hypophosphataemic osteomalacia. Peacock M; Aaron JE; Heyburn PJ; Nordin BE Adv Exp Med Biol; 1977; 81():431-40. PubMed ID: 899935 [No Abstract] [Full Text] [Related]
16. Influence of 1 alpha-hydroxy vitamin D3 (0.25 micrograms/day) and calcium carbonate on patients with chronic renal failure at the predialytic stage. Okada K; Nagura Y; Takahashi S; Hatano M Nihon Jinzo Gakkai Shi; 1989 Jun; 31(6):657-60. PubMed ID: 2795995 [TBL] [Abstract][Full Text] [Related]
17. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Henderson RG; Russell RG; Ledingham JG; Smith R; Oliver DO; Walton RJ; Small DG; Preston C; Warner GT Lancet; 1974 Mar; 1(7854):379-84. PubMed ID: 4131033 [No Abstract] [Full Text] [Related]
18. The effect of 1alpha-hydroxyvitamin D3 in patients with chronic renal failure, with particular emphasis on the renal handling of phosphate. Madsen S; Olgaard K Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():85s-89s. PubMed ID: 606430 [No Abstract] [Full Text] [Related]
19. Association of conjunctival and corneal calcification with vascular calcification in dialysis patients. Seyahi N; Altiparmak MR; Kahveci A; Yetik H; Kanberoglu K; Serdengecti K; Ataman R; Erek E Am J Kidney Dis; 2005 Mar; 45(3):550-6. PubMed ID: 15754277 [TBL] [Abstract][Full Text] [Related]
20. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2. Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R Nephron; 1992; 60(2):154-63. PubMed ID: 1552999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]